Tivantinib

DB12200InvestigationalSmall molecule

Tivantinib has been investigated in Solid Tumors.

Mechanism: Tivantinib mediates its effects by inhibiting the activity of c-Met, a receptor tyrosine kinase that plays multiple key roles in human cancer, including cancer cell growth, survival, angiogenesis, invasion and metastasis. C-Met is abnormally activated in most cancers and is believed to control multiple signal transduction pathways involved in tumor growth and metastasis.
Curator reviewed
Formula / weight: C₂₃H₁₉N₃O₂ · 369.424 g/mol (avg)
Code names: ARQ-197

Resolves to

Compound

Structure

InChIKeyUCEQXRCJXIVODC-PMACEKPBSA-NSMILESO=C1NC(=O)[C@H]([C@@H]1C1=CNC2=CC=CC=C12)C1=CN2CCCC3=C2C1=CC=C3

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

39Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tivantinib, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.